GlassScriptPhysician profile
Himakshi N Bhatt
NPI 1356913347
$4,615.58
in general payments reported to CMS, 2019-2025
20 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $508 · 2022: $930 · 2023: $944 · 2024: $1,043 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,177.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $878.44 | 2022-2025 | Photrexa, Kxl System (Not Refurbished), Kxl1b-Ce-Marked Kxlsystem |
| Sun Pharmaceutical Industries INC. | $726.82 | 2021-2025 | Cequa |
| Alcon Vision LLC | $565.35 | 2023-2025 | Rocklatan, Tryptyr, Rhopressa |
| Bausch & Lomb Americas INC. | $417.07 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $329.48 | 2022-2024 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $317.64 | 2023-2025 | Durysta, Alphagan P, Vuity |
| Tarsus Pharmaceuticals, INC. | $224.39 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $208.58 | 2021-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $170.69 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2021 | |
| Rxsight INC | $116.76 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Coopervision INC. | $96.88 | 2022 | |
| New World Medical,INC. | $94.77 | 2022 | |
| Biotissue Holdings INC. | $94.17 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $62.26 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $57.63 | 2024 | Tecnis Iol, Tecnis Simplicity |
| Kala Pharmaceuticals, INC. | $52.41 | 2022 | |
| Rayner Intraocular Lenses Limited | $42.15 | 2024 | Rayone Emv, Omidria, Rayone Aspheric |
| Harrow Eye, LLC | $20.78 | 2024 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Himakshi Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.